<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Identical proline--&gt;arginine gain-of-function mutations in fibroblast growth factor receptor (FGFR) 1 (Pro252Arg), FGFR2 (Pro253Arg) and FGFR3 (Pro250Arg), result in type I Pfeiffer, <z:e sem="disease" ids="C0001193" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Apert</z:e> and Muenke <z:hpo ids='HP_0001363'>craniosynostosis</z:hpo> syndromes, respectively </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we characterize the effects of proline--&gt;arginine mutations in FGFR1c and FGFR3c on ligand binding using surface plasmon resonance and X-ray crystallography </plain></SENT>
<SENT sid="2" pm="."><plain>Both Pro252Arg FGFR1c and Pro250Arg FGFR3c exhibit an enhancement in ligand binding in comparison to their respective <z:mp ids='MP_0002169'>wild-type</z:mp> receptors </plain></SENT>
<SENT sid="3" pm="."><plain>Interestingly, binding of both mutant receptors to FGF9 was notably enhanced and implicates FGF9 as a potential pathophysiological ligand for mutant FGFRs in mediating <z:hpo ids='HP_0001363'>craniosynostosis</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>The crystal structure, of Pro252Arg FGFR1c in complex with FGF2, demonstrates that the enhanced ligand binding is due to an additional set of receptor-ligand hydrogen bonds, similar to those gain-of-function interactions that occur in the <z:e sem="disease" ids="C0001193" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Apert syndrome</z:e> Pro253Arg FGFR2c-FGF2 crystal structure </plain></SENT>
<SENT sid="5" pm="."><plain>However, unlike the <z:e sem="disease" ids="C0001193" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Apert syndrome</z:e> Pro253Arg FGFR2c mutant, neither the Pfeiffer syndrome Pro250Arg FGFR1c mutant nor the Muenke syndrome Pro250Arg FGFR3c mutant bound appreciably to FGF7 or FGF10 </plain></SENT>
<SENT sid="6" pm="."><plain>This observation provides a potential explanation for why the limb phenotypes, observed in type I Pfeiffer and Muenke syndromes, are less severe than the <z:hpo ids='HP_0002813'>limb abnormalities</z:hpo> observed in <z:e sem="disease" ids="C0001193" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Apert syndrome</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Hence, although analogous proline--&gt;arginine mutations in FGFR1-3 act through a common structural mechanism to result in gain-of-function, differences in the primary sequence among FGFRs result in varying effects on ligand binding specificity </plain></SENT>
</text></document>